Erudio Healtherudio.com
Drug
Daraxonrasib trials: what clinicians said in public
HCP commentary reports on 5 clinical trials studying daraxonrasib, including RASolute 309, RASolve 301, RMC-6236-001 and RMC-9805-001. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 7 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| RASolute 309 NCT07805954 · Revolution Medicines, Inc. | first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma | Phase 3 | 139 | 24 | Focused | Nov 16, 2026 | Preview |
| RMC-6236-001 NCT05379985 · Revolution Medicines, Inc. | RAS-mutant advanced solid tumors | Phase 1/Phase 2 | 196 | 50 | Standard | Nov 4, 2026 | Preview |
| RMC-9805-001 NCT06040541 · Revolution Medicines, Inc. | advanced KRAS G12D-mutant solid tumors | Phase 1 | 117 | 46 | Focused | Nov 2, 2026 | Preview |
| RMC-GI-102 NCT06445062 · Revolution Medicines, Inc. | metastatic colorectal cancer or pancreatic ductal adenocarcinoma | Phase 1/Phase 2 | 38 | 19 | Focused | Oct 29, 2026 | Preview |
| RASolve 301 NCT06881784 · Revolution Medicines, Inc. | previously treated RAS-mutant NSCLC | Phase 3 | 97 | 24 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RASolute 302 NCT06625320 · Revolution Medicines, Inc. DeepView → | previously treated metastatic pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| RASolute 303 NCT07491445 · Revolution Medicines, Inc. DeepView → | first-line metastatic pancreatic adenocarcinoma | Phase 3 | Deep | View | |||
| RASolute 304 NCT07252232 · Revolution Medicines, Inc. DeepView → | resected pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| NCT06922591 NCT06922591 · Tango Therapeutics, Inc. FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT06128551 NCT06128551 · Revolution Medicines, Inc. FocusedView → | advanced KRAS G12C-mutated solid tumors | Phase 1/Phase 2 | Focused | View | |||
| NCT06162221 NCT06162221 · Revolution Medicines, Inc. FocusedView → | advanced RAS-mutated NSCLC | Phase 1/Phase 2 | Focused | View | |||
| MTAPESTRY 103 NCT06360354 · Amgen FocusedView → | Not given | Phase 1 | Focused | View | |||